Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, January 3rd:

Sensus Healthcare


SRTS

: This medical device company has a Zacks Rank #1 (Strong Buy) and witnessed the Zacks Consensus Estimate for its next year earnings increasing 75% over the last 60 days.

Sensus Healthcare’s shares gained 95.4% over the last three month compared with the S&P 500’s growth of 10.6%. The company possesses a

Momentum Score

of A.

ANI Pharmaceuticals


ANIP

: This specialty pharmaceutical company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its next year earnings increasing 1.5% over the last 60 days.

ANI Pharmaceuticals’ shares gained 39.8% over the last three month compared with the S&P 500’s growth of 10.6%. The company possesses a Momentum Score of A.

AutoZone


AZO

: This company which is one of the leading specialty retailers and distributor of automotive replacement parts and accessories in the United States has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 9.3% over the last 60 days.

AutoZone’s shares gained 27.6% over the last three month compared with the S&P 500’s growth of 10.6%. The company possesses a Momentum Score of B.

See the

full list of top ranked stocks here

Learn more about the

Momentum score and how it is calculated here

.

Zacks Top 10 Stocks for 2022

In addition to the investment ideas discussed above, would you like to know about our 10 top picks for the entirety of 2022?

From inception in 2012 through November, the

Zacks Top 10 Stocks

gained an impressive +962.5% versus the S&P 500’s +329.4%. Now our Director of Research is combing through 4,000 companies covered by the Zacks Rank to handpick the best 10 tickers to buy and hold. Don’t miss your chance to get in on these stocks when they’re released on January 3.

Be First To New Top 10 Stocks >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.

Click to get this free report

To read this article on Zacks.com click here.

Zacks Investment Research